NASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Price, News & Analysis → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free SRPT Stock Alerts $129.86 +5.41 (+4.35%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$125.40▼$130.8050-Day Range$113.33▼$136.0452-Week Range$55.25▼$146.68Volume16.98 million shsAverage Volume1.23 million shsMarket Capitalization$12.27 billionP/E Ratio1,180.55Dividend YieldN/APrice Target$164.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Sarepta Therapeutics alerts: Email Address Sarepta Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside26.3% Upside$164.00 Price TargetShort InterestBearish6.94% of Shares Sold ShortDividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews Sentiment0.65Based on 21 Articles This WeekInsider TradingSelling Shares$3.25 M Sold Last QuarterProj. Earnings Growth182.85%From $2.74 to $7.75 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.76 out of 5 starsMedical Sector48th out of 929 stocksPharmaceutical Preparations Industry17th out of 438 stocks 4.4 Analyst's Opinion Consensus RatingSarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sarepta Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.94% of the outstanding shares of Sarepta Therapeutics have been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Sarepta Therapeutics has recently increased by 15.29%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSarepta Therapeutics has received a 62.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Sarepta Therapeutics is -1.65. Previous Next 3.1 News and Social Media Coverage News SentimentSarepta Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Sarepta Therapeutics this week, compared to 9 articles on an average week.Search Interest22 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat Follows8 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,248,319.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sarepta Therapeutics' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow by 182.85% in the coming year, from $2.74 to $7.75 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is 1,180.55, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 139.60.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is 1,180.55, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 176.97.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 12.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sarepta Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About Sarepta Therapeutics Stock (NASDAQ:SRPT)Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Read More SRPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRPT Stock News HeadlinesMay 7, 2024 | insidertrades.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Insider Dallan Murray Sells 3,635 SharesMay 31 at 5:45 PM | businesswire.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 31 at 8:28 AM | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Earns Overweight Rating from Analysts at Piper SandlerMay 29 at 5:32 PM | ca.finance.yahoo.comI:RUT Oct 2024 Weekly 2200.000May 29 at 5:32 PM | ca.finance.yahoo.comI:RUT Jun 2024 Weekly 1685.000May 29 at 5:32 PM | msn.comWith FDA Decision Date Approaching, Analyst Downgrades Sarepta On Balanced Risk And RewardMay 29 at 12:32 PM | finance.yahoo.comIs Sarepta Therapeutics, Inc. (NASDAQ:SRPT) A Good Fast Growth Stock To Buy?May 29 at 2:48 AM | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Receives Sector Perform Rating from Royal Bank of CanadaMay 28, 2024 | msn.comRBC Capital cuts Sarepta to sector perform ahead of FDA decisionMay 28, 2024 | msn.comRBC Capital Downgrades Sarepta Therapeutics (SRPT)May 28, 2024 | msn.comSarepta Downgraded As FDA Decision Date Approaches, Shares Up 50% Over Last Six MonthsMay 28, 2024 | ca.finance.yahoo.comSRPT Jun 2024 143.000 callMay 24, 2024 | benzinga.comDecoding Sarepta Therapeutics's Options Activity: What's the Big Picture?May 24, 2024 | finance.yahoo.comImplied Volatility Surging for Sarepta (SRPT) Stock OptionsMay 23, 2024 | investorplace.comThe 2030 Millionaire's Club: 3 Biotech Stocks to Buy NowMay 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (DH) and Sarepta Therapeutics (SRPT)May 22, 2024 | benzinga.comJim Cramer: This Industrial Stock Is Doing 'Very Well'; Here's His Take On PalantirMay 22, 2024 | americanbankingnews.comSarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT)May 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Sol-Gel Technologies (SLGL)May 20, 2024 | markets.businessinsider.com12 Analysts Have This To Say About Sarepta TherapeuticsMay 17, 2024 | markets.businessinsider.comBuy Rating for Sarepta Therapeutics’ Elevidys Supported by Positive Regulatory SignalsMay 14, 2024 | msn.comRoblox downgraded, Western Digital initiated: Wall Street's top analyst callsMay 14, 2024 | msn.comOppenheimer Upgrades Sarepta Therapeutics (SRPT)May 14, 2024 | msn.comSarepta upgraded at Oppenheimer on potential Elevidys label expansionMay 5, 2024 | finance.yahoo.comEarnings Beat: Sarepta Therapeutics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsSee More Headlines Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today5/31/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CUSIPN/A CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees1,314Year Founded1980Price Target and Rating Average Stock Price Target$164.00 High Stock Price Target$224.00 Low Stock Price Target$109.00 Potential Upside/Downside+26.3%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$0.11 Trailing P/E Ratio1,180.55 Forward P/E Ratio47.39 P/E GrowthN/ANet Income$-535,980,000.00 Net Margins1.20% Pretax Margin2.43% Return on Equity2.20% Return on Assets0.58% Debt Debt-to-Equity Ratio1.18 Current Ratio4.05 Quick Ratio3.44 Sales & Book Value Annual Sales$1.24 billion Price / Sales9.87 Cash FlowN/A Price / Cash FlowN/A Book Value$10.17 per share Price / Book12.77Miscellaneous Outstanding Shares94,520,000Free Float87,246,000Market Cap$12.27 billion OptionableOptionable Beta0.95 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Douglas S. Ingram Esq. (Age 61)President, CEO & Director Comp: $1.62MMr. Ian Michael Estepan (Age 48)Executive VP & CFO Comp: $917.53kDr. Louise R. Rodino-Klapac Ph.D. (Age 46)Executive VP, Chief Scientific Officer and Head of Research & Development Comp: $1.04MMr. Ryan E. Brown J.D. (Age 46)Executive VP, General Counsel & Corporate Secretary Comp: $823.36kMr. Bilal Arif (Age 52)Executive VP & Chief Technical Operations Officer Ms. Francesca T. NolanExecutive Director of Investor Relations and Corporate CommunicationsMs. Alison NasisiExecutive VP & Chief People OfficerDr. Diane L. Berry Ph.D.Executive VP and Chief of Global Policy & Advocacy OfficerMr. Dallan MurrayExecutive VP & Chief Customer OfficerMr. Will TiltonSenior VP, Head of Strategy & Chief of StaffMore ExecutivesKey CompetitorsMirati TherapeuticsNASDAQ:MRTXPTC TherapeuticsNASDAQ:PTCTACADIA PharmaceuticalsNASDAQ:ACADWave Life SciencesNASDAQ:WVESolid BiosciencesNASDAQ:SLDBView All CompetitorsInsiders & InstitutionsGarde Capital Inc.Bought 1,085 shares on 5/29/2024Ownership: 0.001%Farallon Capital Management LLCBought 1,243,427 shares on 5/24/2024Ownership: 2.596%Cetera Investment AdvisersBought 2,590 shares on 5/24/2024Ownership: 0.013%Tidal Investments LLCBought 228 shares on 5/17/2024Ownership: 0.003%New Covenant Trust Company N.A.Bought 249 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SRPT Stock Analysis - Frequently Asked Questions Should I buy or sell Sarepta Therapeutics stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SRPT shares. View SRPT analyst ratings or view top-rated stocks. What is Sarepta Therapeutics' stock price target for 2024? 15 brokers have issued 12 month price targets for Sarepta Therapeutics' shares. Their SRPT share price targets range from $109.00 to $224.00. On average, they expect the company's stock price to reach $164.00 in the next year. This suggests a possible upside of 26.3% from the stock's current price. View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts. How have SRPT shares performed in 2024? Sarepta Therapeutics' stock was trading at $96.43 on January 1st, 2024. Since then, SRPT stock has increased by 34.7% and is now trading at $129.86. View the best growth stocks for 2024 here. When is Sarepta Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our SRPT earnings forecast. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its earnings results on Wednesday, May, 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.84. The biotechnology company earned $413.50 million during the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a trailing twelve-month return on equity of 2.20% and a net margin of 1.20%. The business's revenue for the quarter was up 63.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.44) EPS. What ETFs hold Sarepta Therapeutics' stock? ETFs with the largest weight of Sarepta Therapeutics (NASDAQ:SRPT) stock in their portfolio include Simplify Health Care ETF (PINK), Morningstar US Small Growth (MSGR), iShares Genomics Immunology and Healthcare ETF (IDNA), iShares Neuroscience and Healthcare ETF (IBRN), Global X Genomics & Biotechnology ETF (GNOM), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and VanEck Biotech ETF (BBH). What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO? 15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS). Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.31%), Janus Henderson Group PLC (5.18%), Capital International Investors (5.10%), Farallon Capital Management LLC (2.60%), Jacobs Levy Equity Management Inc. (0.61%) and Price T Rowe Associates Inc. MD (0.53%). Insiders that own company stock include Bilal Arif, Dallan Murray, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Ian Michael Estepan, Kathryn Jean Boor, Louise Rodino-Klapac, Michael Andrew Chambers, Richard Barry and Stephen Mayo. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Sarepta Therapeutics have any subsidiaries? The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.Read More This page (NASDAQ:SRPT) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsBiden Nomination CANCELED?The Freeport Society[Urgent!] Generational Wealth GameplanCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.